Mod GRF and GHRP-2 is a research peptide blend combining GHRH and ghrelin receptor agonists for experimental GH axis modeling. Mod GRF (CJC-1295 no DAC) engages GHRH receptor–driven cAMP/PKA signaling, while GHRP-2 binds GHS-R1a, activating Gq/11-mediated calcium release. This blend is applied in preclinical studies to analyze peptide synergy, pituitary signaling, and endocrine regulation mechanisms.
For research use only. Not for human consumption.
References:
Bowers CY et al., Endocrinology, 1990 126(2):1165–1171
Teichman SL et al., J Clin Endocrinol Metab, 2006 91(2):479–487
Kojima M et al., Nature, 1999 402(6762):656–660
New
Mod GRF, GHRP-6 10mg (Blend)
$95.00
Mod GRF and GHRP-2 is a research peptide blend combining GHRH and ghrelin receptor agonists for experimental GH axis modeling. Mod GRF (CJC-1295 no DAC) engages GHRH receptor–driven cAMP/PKA signaling, while GHRP-2 binds GHS-R1a, activating Gq/11-mediated calcium release. This blend is applied in preclinical studies to analyze peptide synergy, pituitary signaling, and endocrine regulation mechanisms.
Description
Shipping & Delivery
Related products
BPC-157, TB-500, KPV, GHK-Cu 80mg (Klow Blend)
BPC-157 has undergone a great deal of research because its healing abilities extend well beyond the lining of the stomach. Studies in animal models indicate that BPC-157 can enhance angiogenesis, promote wound healing, stimulate collagen synthesis, modulate the inflammatory response, and protect against oxidative stress. The peptide has shown benefits in animal models with inflammatory bowel disease, GI ulcers, musculoskeletal injuries, heart damage, eye injuries and neurological damage. Research has shown that the oral bioavailability of BPC-157 is quite high. 
Dihexa (5mg x 60 Capsules = 300mg)
Dihexa is a small peptide-derived compound designed to support cognitive function and brain regeneration. It acts by activating the HGF/c-Met signaling pathway, which plays a critical role in forming new synaptic connections and enhancing neuroplasticity. Dihexa also mimics the action of brain-derived neurotrophic factor (BDNF), a key molecule involved in learning, memory, and neuronal survival. Preclinical research studies have shown that Dihexa can significantly improve memory consolidation and reverse cognitive deficits in models of Alzheimer’s disease, traumatic brain injury, and stroke. Unlike traditional nootropics or growth factors with poor blood–brain barrier penetration, Dihexa is orally bioavailable and metabolically stable, allowing for targeted CNS effects. Its unique mechanism positions it as a promising research compound for neurodegenerative conditions, offering potential in synaptic repair, inflammation reduction, and long-term cognitive enhancement. 
Melanotan 2 (MT2) (3mg x 10 Vials = 30mg)
Melanotan-2 (MT-2) is a synthetic derivative of human alpha-melanocyte-stimulating hormone (α-MSH), developed at the University of Arizona in the 1980s. The initial purpose was to create a sunless tanning alternative, inspired by α-MSH's ability to induce sexual arousal and skin darkening in rodents. However, as research progressed, MT-2's diverse effects were unveiled. These include enhancing sexual arousal, promoting skin pigmentation, reducing compulsive behavior, managing addiction, suppressing hunger, decreasing glucagon production, and even potentially reversing certain features associated with autism. Melanotan-2 research has shown it to enhance sexual arousal, promote skin pigmentation through melanocyte activation and reduce compulsive/addictive behaviors.
Reviews
There are no reviews yet.